Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study determined the optimal starting dose of patiromer in treating hyperkalemia in
participants with hypertension and diabetic nephropathy who were already receiving ACEI
and/or ARB drugs, with or without spironolactone. This study also evaluated the efficacy and
safety of patiromer and the long term use of patiromer.